Takeda Pharmaceutical Co Ltd TAK.N, TAK is expected to show a rise in quarterly revenue when it reports results on October 31 for the period ending September 30 2024
The Chuo-ku Tokyo-to-based company is expected to report a 3.9% increase in revenue to JPY1.084 trillion from JPY1.04 trillion a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
LSEG's mean analyst estimate for Takeda Pharmaceutical Co Ltd is for earnings of JPY87.45 per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the pharmaceuticals peer group is also "Buy".
Wall Street's median 12-month price target for Takeda Pharmaceutical Co Ltd is $16.30, above its last closing price of $13.60.
This summary was machine generated October 29 at 11:21 GMT. All figures in yen unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。